FindTrial
Sign In

Efficacy of subconjunctival conbercept injection for corneal neovascularization caused by Chemical injury

Efficacy of subconjunctival conbercept injection for corneal neovascularization caused by Chemical injury

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16010208
Enrollment
Unknown
Registered
2016-12-21
Start date
2016-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ocular chemical injury.

Interventions

The treatment group:subconjunctival conbercept injection 0.05 ml(10 mg/ml)

Sponsors

Eye & ENT Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients aged between 18 to 65 years old; 2. Patients suffered with ocular chemical injury; 3. Clinical diagnosis of corneal neovascularization and in stable condition.

Exclusion criteria

Exclusion criteria: 1. Uncontrolled hypertension; 2. History of thromboembolic event e.g. myocardial infarction, cerebral vascular accident; 3. Diabetic Retinopathy; 4. Hepatic or coagulation function dysfunction; 5. Pregnancy or lactation; 6. Concurrent use hormone therapy; 7. Ocular surgery in the past 1 months.

Design outcomes

Primary

MeasureTime frame
The percentage of corneal neovascularization area;—

Countries

China

Contacts

Public ContactLan Gong

Eye & ENT Hospital of Fudan University

13501798683@139.com+86 13501798683

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026